Best Cell Therapy Companies in China
The 30 best Cell Therapy companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CARsgen.
- ResearchAndMarkets.com
Ranked: Best Cell Therapy companies in China
| # | Company | Disclosed funding | Last round | Stage | Founded | Founder | Employees | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CARsgen Developer of CAR-T cell therapies for the treatment of hematological malignancies and solid tumors | $276M | 72 mo ago | Public | 2014 | Huamao Wang Co-Founder & COO | 525 | — | — |
| 2 | Gracell Bio Developer of CAR T cell therapies for the treatment of cancer | $195M | 39 mo ago | Acquired | 2017 | Wei Cao Founder & CEO | 9 | — | — |
| 3 | OriCell Therapeutics Developer of immuno-therapeutics for cancer treatment 72Funding top 16%Patents top 27%Moat top 28%Innovation top 34% All 8 signals ▾Fundingtop 16% Patentstop 27% Moattop 28% Innovationtop 34% Newstop 36% Markettop 37% Talentbottom 49% Globalbottom 43% Funding: Raised $170M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Patents: 56 patents matched (strict assignee match) · 55 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $170M | 7 mo ago | Series D | 2015 | He Xiaowen Co-Founder | 150 | 56 patents Targeted antibody and CAR‑T therapeutics against hematologic/solid tumor antigens | — |
| 4 | Legend Biotechnology Developer of cell therapy to treat cancer and infectious diseases | $150M | 43 mo ago | Public | 2014 | Yuan Xu CEO | 1,576 | — | — |
| 5 | Innovative Cellular Therapeutics Developer of CAR-T cell therapies for blood cancers and solid tumors | $97M | 62 mo ago | Series C | 2009 | Lei Xiao CEO | 14 | 73 patents Engineered immune cells for enhanced migration, expansion, and checkpoint resistance in cell therapy | — |
| 6 | Neukio Biotherapeutics Developer of cell therapies to treat cancer | $50M | 50 mo ago | Series A | 2021 | Liqun Wang Founder | — | 9 patents Therapeutic antibodies and engineered immune cells for cancer immunotherapy | — |
| 7 | TCRCure Biopharma Developer of cell therapies to treat cancer | $47M | 57 mo ago | Series B | 2016 | — | 70 | 51 patents Engineered immune cell therapies with synthetic cytokine receptors and checkpoint antibodies | — |
| 8 | Shize Bio Developer of stem-cell therapies to treat neurodegenerative diseases 42Funding top 33%Growth top 35%Talent top 38%Moat top 48% All 7 signals ▾Fundingtop 33% Growthtop 35% Talenttop 38% Moattop 48% Marketbottom 48% Globalbottom 29% Techbottom 16% Funding: Raised $41.7M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 42/100 | $42M | 24 mo ago | Series B | 2021 | Michael Lee Founder & CEO | 100 | — | — |
| 9 | Huaxia Yingtai Biotechnology Developer of CAR-T cell therapies for treating cancer | $38M | 61 mo ago | Series B | 2018 | Lin Xin Founder | — | — | — |
| 10 | Hebei Senlang Biotechnology Developer of CAR-T cell based immunotherapy for cancer | $30M | 54 mo ago | Acquired | 2017 | — | 160 | 21 patents Nanobody-based CAR immunotherapies targeting CD7, CLDN18.2, and BCMA for cancer treatment | — |
| 11 | Starna Therapeutics Developer of RNA-based drugs for multiple diseases 29Funding top 34%Moat top 38%Talent bottom 49%Market bottom 37% All 5 signals ▾Fundingtop 34% Moattop 38% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $22.1M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $22M | 13 mo ago | Series B | 2021 | Rongkuan Hu Founder | — | — | — |
| 12 | Nk-Celltech Provider of immuno-oncologic drugs for cancer 40Market top 45%Funding top 46%Global bottom 38% All 3 signals ▾Markettop 45% Fundingtop 46% Globalbottom 38% Market: 60 employees (top 31% of Life Sciences) Funding: Raised $14.9M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $15M | 16 mo ago | Series A | 2020 | — | 60 | — | — |
| 13 | Nanjing CART Medical Technologies Developer and provider of CAR T cell therapy related technologies and services | $10M | 57 mo ago | Series A | 2017 | Enxiu Wang Founder | — | — | — |
| 14 | Chengdu Kangjing Biotechnology Developer of stem cell and immune cell therapy technology | $4M | 145 mo ago | Seed | 2013 | — | 60 | — | — |
Top 12 Cell Therapy companies in China
#1
Series D · Pudong, Shanghai · founded 2015 · 150 employees$170Mraised▾
Developer of immuno-therapeutics for cancer treatment. It offers CAR-T- based therapies and antibodies for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, non-small cell lung cancer, and others.
- Apr 2026Series D$110M
- Jan 2026Series C$70M
- Feb 2023Series B$45M
- Aug 2022Series B$125M
#2
Series B · Suzhou, Jiangsu · founded 2021$22.1Mraised▾
Developer of RNA-based drugs for multiple diseases. The company focuses on the development of innovative drugs and vaccines with RNA as the core for infectious diseases, tumor immunology, and metabolic diseases.
- Oct 2025Series B$44M
- May 2022Series A$22.1M
- Dec 2021Angel—
#3
Series A · Pudong, Shanghai · founded 2020 · 60 employees$14.9Mraised▾
Provider of NK cell therapy for treating cancer, cellular drugs to precisely target of tumors and tumor immune microenvironment (TIME)
- Jul 2025Series A$13.9M
- Jul 2022Series A$14.9M
#4
Series B · Minhang, Shanghai · founded 2021 · 100 employees$41.7Mraised▾
Developer of stem-cell therapies to treat neurodegenerative diseases. By using gene-editing technology, the company has engineered a pluripotent stem cell platform to develop therapeutics for degenerative diseases such as Parkinson's disease.
- Oct 2024Series B$14M
- Apr 2023Series A—
- Nov 2022Series A$27.7M
- Jan 2022Seed—
#5
Acquired · Shanghai, Shanghai · founded 2017 · 9 employees$195.2Mraised▾
Developer of CAR T cell therapies for the treatment of cancer. The company has developed a gene-editing platform to produce multiplex CAR T cell therapies such as FasTCAR, TruUCAR, and Donor-derived CAR for multiple myeloma, lymphoma, and leukemia. The company is also working on a combination of CAR-T with co-stimulatory factors.
- Aug 2023Post IPO—
- Oct 2020Series C$100M
- Feb 2019Series B$85M
- Sep 2018Series A$10.2M
#6
Public · Nanjing, Jiangsu · founded 2014 · 1576 employees$150.4Mraised▾
Developer of cell therapy to treat cancer and infectious diseases. The company focused on developing CAR-T cell therapies for hematologic malignancies, solid tumors, and infectious diseases.
- Apr 2023Post IPO$200M
- Mar 2020Series D$150.4M
#7
Public · Shanghai, Shanghai · founded 2014 · 525 employees$276Mraised▾
Developer of CAR-T cell therapies for the treatment of hematological malignancies and solid tumors. The company's lead product is KJgpc3-001, a glypican-3 (GPC3)-directed CAR-T cell therapy for liver cancer, and is also advancing CAR-T therapies for lung and brain cancers in parallel.
- Nov 2020Series C$186M
- Mar 2018Series B$60M
- Jan 2016Series B$30M
- Nov 2014Series A—
#8
Series C · Shanghai, Shanghai · founded 2009 · 14 employees$97.1Mraised▾
Developer of CAR-T cell therapies for blood cancers and solid tumors. The company has a CoupledCAR technology platform to develop a pipeline of drugs for colorectal, thyroid, pancreatic, and lung cancer.
- Sep 2021Series C$40M
- Dec 2019Series B$28.6M
- Apr 2018Series B$28.5M
#9
Series A · Shanghai, Shanghai · founded 2021$50Mraised▾
Developer of cell therapies to treat cancer. The company leverages gene-editing technologies and focuses on the development of iPSC-CAR-NK immune cell therapies to treat cancer patients.
- Sep 2022Series A$50M
#10
Series B · Beijing, Beijing · founded 2016 · 70 employees$47.3Mraised▾
Developer of cell therapies to treat cancer. The company has developed a T cell engineering platform that enables antigen-specific TCR cloning, T cell genetic engineering, and TCR repertoire analysis. They are planning to initiate clinical trials for the treatment of HPV-related cervical and head/neck cancers.
- Feb 2022Series B$47.3M
- Apr 2019Series A—
- Dec 2018Series A—
- 2017Series A—
#11
Acquired · Shijiazhuang, Hebei · founded 2017 · 160 employees$29.6Mraised▾
Hebei Senlang Biotechnology is developing immunotherapy-based technology to treat cancer. They have developed an immunotherapy platform based on CAR-T/TCR-T, universal CAR-GDT, and CAR-HSPC-NK technology. Their lead candidate CD19 CAR-T, has completed preclinical phase which is being investigated for hematological tumor.
- May 2022Series C$29.6M
- 2018Series B—
#12
Series B · Haidian, Beijing · founded 2018$37.5Mraised▾
Developer of CAR-T cell therapies for treating cancer. The company has T cell transformation technology platforms, STAR-T and TCR-T, and has built a mature industrialization platform for process development and quality control. It is developing pipeline of products for treatment of hematological tumors and other indfectious diseases.
- Oct 2021Series B$31M
- Jan 2020Series A$6.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cell Therapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising